David D Berg1, Eugene Braunwald2, Adam D DeVore3, Anuradha Lala4, Sean P Pinney4, Carol I Duffy5, Yared Gurmu2, Eric J Velazquez6, David A Morrow2. 1. TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: dberg1@bwh.harvard.edu. 2. TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Duke Clinical Research Institute, Duke University, Durham, North Carolina. 4. Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 6. Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Abstract
OBJECTIVES: This study sought to evaluate the efficacy and safety of sacubitril/valsartan according to dose level achieved in the PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode) trial. BACKGROUND: In patients hospitalized for acute decompensated heart failure (ADHF), in-hospital initiation and continuation of sacubitril/valsartan as compared with enalapril is well tolerated, achieves a greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP), and reduces the risk of cardiovascular death or rehospitalization for HF through 8 weeks. However, not all patients achieve the target dose of sacubitril/valsartan, and its efficacy and safety in such patients are of interest. METHODS: PIONEER-HF was a randomized, double-blind, active-controlled trial of sacubitril/valsartan versus enalapril in 881 patients stabilized during hospitalization for ADHF. Blinded study medication was administered for 8 weeks, with initial dosing selected based on the systolic blood pressure at randomization and titrated toward a target of sacubitril/valsartan 97/103 mg twice daily, or enalapril 10 mg twice daily, with an algorithm based on systolic blood pressure and the investigator's assessment of tolerability. RESULTS: At 4 weeks, 199 (55%) patients allocated to sacubitril/valsartan and 211 (60%) patients allocated to enalapril were dispensed the target dose. Baseline characteristics were similar in the 2 treatment groups within each dose level. There was no heterogeneity across dose levels in the effect of sacubitril/valsartan on the reduction in NT-proBNP (pinteraction = 0.69), the reduction in cardiovascular death or rehospitalization for heart failure (pinteraction = 0.42), or the pre-specified adverse events of special interest through 8 weeks. CONCLUSIONS: In hemodynamically stabilized patients with ADHF, the efficacy and safety of sacubitril/valsartan are generally consistent across dose levels. (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890).
RCT Entities:
OBJECTIVES: This study sought to evaluate the efficacy and safety of sacubitril/valsartan according to dose level achieved in the PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode) trial. BACKGROUND: In patients hospitalized for acute decompensated heart failure (ADHF), in-hospital initiation and continuation of sacubitril/valsartan as compared with enalapril is well tolerated, achieves a greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP), and reduces the risk of cardiovascular death or rehospitalization for HF through 8 weeks. However, not all patients achieve the target dose of sacubitril/valsartan, and its efficacy and safety in such patients are of interest. METHODS: PIONEER-HF was a randomized, double-blind, active-controlled trial of sacubitril/valsartan versus enalapril in 881 patients stabilized during hospitalization for ADHF. Blinded study medication was administered for 8 weeks, with initial dosing selected based on the systolic blood pressure at randomization and titrated toward a target of sacubitril/valsartan 97/103 mg twice daily, or enalapril 10 mg twice daily, with an algorithm based on systolic blood pressure and the investigator's assessment of tolerability. RESULTS: At 4 weeks, 199 (55%) patients allocated to sacubitril/valsartan and 211 (60%) patients allocated to enalapril were dispensed the target dose. Baseline characteristics were similar in the 2 treatment groups within each dose level. There was no heterogeneity across dose levels in the effect of sacubitril/valsartan on the reduction in NT-proBNP (pinteraction = 0.69), the reduction in cardiovascular death or rehospitalization for heart failure (pinteraction = 0.42), or the pre-specified adverse events of special interest through 8 weeks. CONCLUSIONS: In hemodynamically stabilized patients with ADHF, the efficacy and safety of sacubitril/valsartan are generally consistent across dose levels. (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890).
Authors: Rolf Wachter; Michele Senni; Jan Belohlavek; Ewa Straburzynska-Migaj; Klaus K Witte; Zhanna Kobalava; Candida Fonseca; Eva Goncalvesova; Yuksel Cavusoglu; Alberto Fernandez; Said Chaaban; Ellen Bøhmer; Anne-Catherine Pouleur; Christian Mueller; Christophe Tribouilloy; Eva Lonn; Jehad A L Buraiki; Jacek Gniot; Maria Mozheiko; Malgorzata Lelonek; Adele Noè; Heike Schwende; Weibin Bao; Dmytro Butylin; Domingo Pascual-Figal Journal: Eur J Heart Fail Date: 2019-05-27 Impact factor: 15.534
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: Eric J Velazquez; David A Morrow; Adam D DeVore; Andrew P Ambrosy; Carol I Duffy; Kevin McCague; Adrian F Hernandez; Ricardo A Rocha; Eugene Braunwald Journal: Am Heart J Date: 2018-01-10 Impact factor: 4.749
Authors: David A Morrow; Eric J Velazquez; Adam D DeVore; Akshay S Desai; Carol I Duffy; Andrew P Ambrosy; Yared Gurmu; Kevin McCague; Ricardo Rocha; Eugene Braunwald Journal: Circulation Date: 2019-05-07 Impact factor: 29.690
Authors: Eric J Velazquez; David A Morrow; Adam D DeVore; Carol I Duffy; Andrew P Ambrosy; Kevin McCague; Ricardo Rocha; Eugene Braunwald Journal: N Engl J Med Date: 2018-11-11 Impact factor: 91.245
Authors: Scott D Solomon; Joanna Dobson; Stuart Pocock; Hicham Skali; John J V McMurray; Christopher B Granger; Salim Yusuf; Karl Swedberg; James B Young; Eric L Michelson; Marc A Pfeffer Journal: Circulation Date: 2007-08-27 Impact factor: 29.690
Authors: Natalie A Bello; Brian Claggett; Akshay S Desai; John J V McMurray; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Scott D Solomon Journal: Circ Heart Fail Date: 2014-05-29 Impact factor: 8.790
Authors: James L Januzzi; Margaret F Prescott; Javed Butler; G Michael Felker; Alan S Maisel; Kevin McCague; Alexander Camacho; Ileana L Piña; Ricardo A Rocha; Amil M Shah; Kristin M Williamson; Scott D Solomon Journal: JAMA Date: 2019-09-17 Impact factor: 56.272
Authors: Orly Vardeny; Brian Claggett; Milton Packer; Michael R Zile; Jean Rouleau; Karl Swedberg; John R Teerlink; Akshay S Desai; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon Journal: Eur J Heart Fail Date: 2016-06-10 Impact factor: 15.534
Authors: David D Berg; Marc D Samsky; Eric J Velazquez; Carol I Duffy; Yared Gurmu; Eugene Braunwald; David A Morrow; Adam D DeVore Journal: Circ Heart Fail Date: 2021-02-03 Impact factor: 8.790
Authors: Nor Hidayah Mustafa; Juriyati Jalil; Satirah Zainalabidin; Mohammed S M Saleh; Ahmad Yusof Asmadi; Yusof Kamisah Journal: Front Pharmacol Date: 2022-08-08 Impact factor: 5.988